Canaccord raised the firm’s price target on Stryker to $300 from $295 and keeps a Hold rating on the shares. The firm noted they detailed financial goals at its Investor Day earlier this month including expanding gross margins and operating margins into 2025 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK:
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Stryker intends to nominate Rachel Ruggeri for board of directors
- Stryker director Srikant Datar to retire
- Stryker announces Dr. Srikant Datar will retire from Board of Directors
- Stryker declares a $0.80 per share quarterly dividend